Posted by Michael Wonder on 12 Mar 2020
AbbVie announces new formulary listings for Skyrizi in the treatment of moderate to severe plaque psoriasis
12 March 2020 - Non-Insured Health Benefits program lists Skyrizi on its formulary effective 21 February 2020.
AbbVie announced today that Skyrizi (risankizumab) is now listed on the formularies of the Non-Insured Health Benefits program and the province of Manitoba for the treatment of moderate to severe plaque psoriasis.
This announcement comes just three months after AbbVie successfully reached an agreement with the pan-Canadian Pharmaceutical Alliance, bringing a much-needed treatment to patients living with psoriasis.
